Global Catalepsy Treatment Market, By Treatment (Drugs, Psychotherapy, Others), Route of Administration (Oral, Parenteral and Others), End-Users (Hospitals, Specialty Clinics, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, online Pharmacies and Others) – Industry Trends and Forecast to 2030.
Catalepsy Treatment Market Analysis and Size
Catalepsy may be caused by a series of conditions. Catalepsy often follows by catatonia, which is a psychomotor disturbance. Catalepsy is one of the twelve symptoms of catatonia. It may be caused by schizophrenia, epilepsy, drug toxicity, or Parkinson disease. Antipsychotic medications and muscle relaxants are two types of treatments that are used to help with catalepsy.
Data Bridge Market Research analyses a growth rate in the catalepsy treatment market in the forecast period 2023-2030. The expected CAGR of catalepsy market is tend to be around 6.20% in the mentioned forecast period. The market value is USD 82 billion in 2022, and it would grow up to USD 132.68 billion by 2030. In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market report curated by the Data Bridge Market Research team also includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Catalepsy Treatment Market Scope and Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2023 to 2030
|
|
Base Year
|
2022
|
|
Historic Years
|
2021 (Customizable to 2015 - 2020)
|
|
Quantitative Units
|
Revenue in USD Billion, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
Treatment (Drugs, Psychotherapy, Others), Route of Administration (Oral, Parenteral and Others), End-Users (Hospitals, Specialty Clinics, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, online Pharmacies and Others)
|
|
Countries Covered
|
U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America
|
|
Market Players Covered
|
GSK Plc. (U.K.), Bayer AG (Germany), Novartis AG (Switzerland), Sanofi (France), Takeda Pharmaceutical Company Limited (Japan), F. Hoffmann-La Roche Ltd (Switzerland), Abbott (U.S.), Pfizer Inc. (U.S.), Mylan N.V. (U.S.), Upsher-Smith Laboratories, LLC (U.S.), Piramal Enterprises Ltd. (India), Vintage Labs (India)., Hikma Pharmaceuticals PLC (U.K.), Endo International plc (Ireland), CASI Pharmaceuticals Inc. (U.S.), ECI Pharmaceuticals (Florida), Bristol-Myers Squibb Company (U.S.), Covis Pharma GmbH (Canada), Sumitomo Pharma Co., Ltd (Japan), Biocon (India), Eisai Co., Ltd (Japan), Cipla Inc (India), Glenmark Pharmaceuticals Limited (India), Mankind Pharma (India), Novo Nordisk A/S (Denmark), Otsuka America Pharmaceutical, Inc (Japan), and WOCKHARDT (India)
|
|
Market Opportunities
|
|
Market Definition
Catalepsy is the state of marked loss of voluntary mobility wherein the limbs remain in whatever posture they are placed. The typical symptoms include muscle rigidity, voluntary motion loss, fixed posture, and diminished pain sensitivity. It can be a sign of numerous of diseases, epilepsy, substance abuse, Parkinson's disease, catatonia, schizophrenia, and as a side effect of certain types of schizophrenia treatment.
Catalepsy Treatment Market Dynamics
Drivers
- Growing Prevalence Of Chronic Diseases
Chronic conditions are on rise worldwide. The unequal intra-urban inequities in access to the wide healthcare services leads to the problems faced by urban people. Elderly people, women and people living below the poverty line had higher odds of chronic conditions. Approximately 80 % of these deaths occur in low- and middle-income countries. The incidence of chronic conditions is increasing worldwide. In 2014, around 60 % of all the deaths in India were because of non-communicable diseases and the high burden is projected to increase over the time. Some common chronic diseases are somewhat increasing the incidence of catalepsy. This boost the treatment market.
Opportunities
- Growing Number Of R&D Activities
Numerous projected introduction of many novel developing drugs and widen availability of advantageous reimbursement policies are expected to have much beneficial effects. Other factors that causes the market expansion includes increased government funding for R&D and improved regulatory environment for the healthcare sector. Numerous technological advancements and greater investments in R&D activities have caused the discovery of several novel treatment options. Numerous new trends, such as companies focusing on increase in research and development spending on different neurological disorders are helping to develop novel medicines for treatment of this syndrome. Additionally, numerous clinical trials are conducted on many compounds; and some are in the research process. Several research showed that medications, such as tricyclic antidepressants, zolpidem, benzodiazepines, carbamazepine, and muscle relaxants may prove to be very effective in decreasing the symptoms of catalepsy. In addition to this, pharmacotherapy of Parkinson-induced catalepsy may include dopamine agonists and decarboxylase inhibitors among others. This enhances the market growth.
Restraints/Challenges
- High Cost of Treatment
The increased expenditure that is required for the treatment processes hampers the market growth. Several market players make vast investments in manufacturing new and advanced treatment procedures to improve the recovery process, and thus in return, the cost is increased. This hampers the market growth.
This catalepsy treatment market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the catalepsy treatment market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
Global Catalepsy Treatment Market Scope
The catalepsy treatment market is segmented on the basis of treatment, route of administration, distribution channel and end-user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Treatment
- Drugs
- Psychotherapy
- Others
Route of Administration
- Oral
- Parenteral
- Others
End-Users
- Hospitals
- Specialty Clinics
- Others
Distribution Channel
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacies
- Others
Catalepsy Treatment Regional Analysis/Insights
The catalepsy treatment market is analyzed and market size insights and trends are provided by treatment, route of administration, distribution channel and end-user as referenced above.
The major countries covered in the Catalepsy treatment market report are the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
North America is dominating the market in the forecast period due to the increased incidence of neurological disorders, advanced technology for the diagnosis and treatment in this region.
Asia-Pacific is considered to grow over the coming years because of the continuously increasing population leading to sincreasing prevalence of neurological disorders.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Competitive Landscape and Global Catalepsy Treatment Share Analysis
The catalepsy treatment market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to catalepsy treatment market
Key players operating in the catalepsy treatment market include:
- GSK Plc. (U.K.)
- Bayer AG (Germany)
- Novartis AG (Switzerland)
- ALEVA NEUROTHERAPEUTICS (Switzerland)
- Sanofi (France)
- Takeda Pharmaceutical Company Limited (Japan)
- F. Hoffmann-La Roche Ltd (Switzerland)
- Abbott (U.S.)
- Pfizer Inc. (U.S.)
- Johnson & Johnson Services, Inc. (India)
- Dr. Reddy’s Laboratories Ltd. (India)
- Mylan N.V. (U.S.)
- Upsher-Smith Laboratories, LLC (U.S.)
- Piramal Enterprises Ltd. (India)
- Vintage Labs (India)
- Hikma Pharmaceuticals PLC (U.K.)
- Endo International plc (Ireland)
- CASI Pharmaceuticals Inc. (U.S.)
- ECI Pharmaceuticals (Florida)
- Bristol-Myers Squibb Company (U.S.)
- Covis Pharma GmbH (Canada)
- Sumitomo Pharma Co., Ltd (Japan)
- Biocon (India), Eisai Co., Ltd (Japan)
- Cipla Inc (India)
- Glenmark Pharmaceuticals Limited (India
- Mankind Pharma (India)
- Novo Nordisk A/S (Denmark)
- Otsuka America Pharmaceutical, Inc (Japan)
- WOCKHARDT (India)
SKU-